Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Celldex ends esophageal program despite hitting primary endpoint
The biotech showed the candidate depletes mast cells in the GI tract, but that positive finding was overshadowed by its failure to improve symptoms.
Nick Paul Taylor
Aug 20, 2025 6:42am
Pfizer's SCD drug fails ph. 3 study in latest blow to GBT legacy
Aug 18, 2025 7:31am
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Aug 13, 2025 1:48pm
Biohaven trashes troriluzole in OCD after ph. 3 fail
Aug 12, 2025 2:06pm
Cancer vaccine's 'narrow' fail won't stop IO heading to FDA
Aug 11, 2025 9:48am
Vertex drops asset in acute pain after phase 2 fail
Aug 4, 2025 5:34pm
